UBS Group
CCCC icon

UBS Group’s C4 Therapeutics CCCC Stock Holding History

UBS Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$568K Buy
215,877
+163,125
+309% +$384K ﹤0.01% 5995
2025
Q4 		$101K Sell
52,752
-8,898
-14% -$21.1K ﹤0.01% 6907
2025
Q3 		$137K Sell
61,650
-510,376
-89% -$1.23M ﹤0.01% 6906
2025
Q2 		$818K Sell
572,026
-300,744
-34% -$437K ﹤0.01% 5612
2025
Q1 		$1.4M Buy
872,770
+114,918
+15% +$343K ﹤0.01% 5006
2024
Q4 		$2.73M Buy
757,852
+423,771
+127% +$2.11M ﹤0.01% 4422
2024
Q3 		$1.9M Sell
334,081
-70,037
-17% -$421K ﹤0.01% 4041
2024
Q2 		$1.87M Sell
404,118
-292,559
-42% -$1.74M ﹤0.01% 3837
2024
Q1 		$5.69M Buy
696,677
+418,302
+150% +$3.24M ﹤0.01% 2836
2023
Q4 		$1.57M Sell
278,375
-43,234
-13% -$98.6K ﹤0.01% 4059
2023
Q3 		$598K Buy
321,609
+51,807
+19% +$158K ﹤0.01% 4520
2023
Q2 		$742K Buy
269,802
+107,152
+66% +$344K ﹤0.01% 4500
2023
Q1 		$511K Sell
162,650
-107,570
-40% -$633K ﹤0.01% 4669
2022
Q4 		$1.59M Sell
270,220
-46,825
-15% -$388K ﹤0.01% 3611
2022
Q3 		$2.78M Sell
317,045
-30,141
-9% -$313K ﹤0.01% 2863
2022
Q2 		$2.62M Buy
347,186
+17,608
+5% +$155K ﹤0.01% 2915
2022
Q1 		$8M Sell
329,578
-13,220
-4% -$321K ﹤0.01% 2119
2021
Q4 		$11M Sell
342,798
-74,555
-18% -$2.95M ﹤0.01% 2056
2021
Q3 		$18.6M Buy
417,353
+15,980
+4% +$684K 0.01% 1556
2021
Q2 		$15.2M Buy
401,373
+138,935
+53% +$4.98M ﹤0.01% 1697
2021
Q1 		$9.71M Buy
262,438
+161,722
+161% +$6.43M ﹤0.01% 1974
2020
Q4 		$3.34M Buy
+100,716
New +$2.92M ﹤0.01% 2882

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group's CCCC Position: Q1 2026 in Review

UBS Group increased its C4 Therapeutics (CCCC) stake by 309% in Q1 2026, buying an estimated $384K and bringing the position to 215,877 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #5995.

UBS Group first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $18.6M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • UBS Group held 215,877 shares of C4 Therapeutics worth $568K as of Q1 2026.
  • UBS Group bought 163,125 C4 Therapeutics shares in Q1 2026, an estimated $384K.
  • C4 Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5995 holding.
  • UBS Group first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • UBS Group's C4 Therapeutics position peaked at $18.6M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.